Who we are
Polyplus, part of Sartorius, is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale.
An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services for viral and non-viral delivery. Custom plasmid vector design and plasmid and protein manufacturing was integrated into the offer in 2022 to expand the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards.
Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia. Since July 2023, Polyplus is now part of Sartorius.
Our mission is to develop innovative solutions that enable scientists to develop breakthrough nucleic acid-based therapies that improve human health.
Founding the company
Polyplus has been driven to innovate solutions for nucleic acid delivery that power your science since January 2001. Originally named Polyplus-transfection, the company shortened the name to Polyplus in 2022, as we began to expand our focus on building our portfolio of purpose fit solutions and services that help customers optimize upstream process economics.
Our vision is to help drug developers and manufacturers innovate with greater confidence and quality while reducing cost and time to market for cell and gene therapies and RNA & DNA therapeutics.
Our Company Values
Growing profitably and acting responsibly towards all stakeholders
Driving change and progress internally and externally
Working in an energetic and rewarding environment
Our Management Team
Mario Philips draws on more than 20 years of scientific expertise, technical innovation, and operational management to lead the team in his role as CEO & Chairman at Polyplus. He has been an active industry advocate throughout his career, driving a great deal of progress in the single use space, and is now leading the charge to optimize upstream process economics for today’s advanced modalities.
Patrick Erbacher (Ph.D.) is a legacy Polyplus employee who joined as a postdoctoral research scientist working in founder, Dr. Behr’s, laboratory of genetic chemistry. During his time at the company, he has invaluably driven scientific strategy, and is a frequent author and inventor with 12 co-authored patent applications and more than 35 scientific publications.
Roel Gordijn has deep expertise in global commercial structure and operations in this evolving industry. He is responsible for building and driving commercial activity with a focus on what the customer is facing while working to accommodate the growing list of modalities in the market.
Chantal Devin-Chaloin (Ph.D.) joined the company with the goal of expanding and securing the global supply chain for Polyplus, customers and partners. She pulls from operations management experience in the contract space to help refine the go to market strategy and customer experience.
Stéphane Béchot joined Polyplus to manage Finance, Administration, IT. His expertise in Financial Consulting, Food industry, Engineering and IT Services have been a great resource to keep the company running efficiently.
Research & Development
Based on its core know-how in the field of nucleic acid engineering and delivery technology, Polyplus ®’s R&D team is focused on developing innovative products for the upstream manufacturing of biologics for advanced medicinal therapy and for the development of nucleic acid-based therapeutics. Our R&D is optimizing key critical components of the manufacturing workflow (plasmids, media, transfection reagents) to increase viral vector titers and quality. Our R&D team is developing also critical materials (plasmids, lipids, polymers) and nanoparticle solutions for novel non-viral RNA/DNA therapeutics.
Join our team
Add value to Human life, where our mission is to develop cutting-edge delivery technologies to enable scientists to develop breakthrough nucleic acid-based therapies as treatment to improve Human health every step of the way from basic science to the clinic.